Premium
Use of calcium isotope tracers for screening potential treatments for osteoporosis
Author(s) -
Hohman Emily E,
Martin Berdine R,
McCabe Linda D,
McCabe George P,
Jackson George S,
Peacock Munro,
Weaver Connie M
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1053.16
Subject(s) - osteoporosis , medicine , bone remodeling , bone mineral , urine , calcium , anabolism , pharmacology , endocrinology , physiology
Determining the efficacy of novel osteoporosis therapies and preventive interventions (ie. dietary supplements) is costly and time consuming when using the traditional endpoints of bone mineral density (BMD) or fracture prevention. Calcium isotope tracers offer a relatively cheap and rapid technique to screen potential osteoporosis therapies in both humans and animals. We have developed methods to screen potential anti‐osteoporosis therapies using 41 Ca in humans and 45 Ca in rats. Following a single dose of the tracer and an equilibration period through one bone remodeling cycle (150d in humans and 30d in rats), the blood and urine clearance of tracer reflects bone turnover, and changes in urine tracer excretion in response to therapy measure changes in net bone turnover. Using this method, efficacy of potential anti‐osteoporosis therapies can be determined in as few as 50 days in humans and 10d in rats, and multiple therapies can be sequentially screened in the same individual. We have utilized this method to compare efficacy of antiresorptives, including bisphosphonates, estrogen, and soy isoflavones, in both humans (Weaver et al. 2009 J Clin Endocrinol Metab) and in rats and have recently confirmed that this method is also suitable for comparing anabolic therapies. These methods will be used in future planned studies to screen botanical products and drug/botanical combination therapies. Grant Funding Source : NIH, Purdue University